Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business And Investment

Innovation Drives Investment But US Election Poses Risk

 
• By Eleanor Malone and Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.

Scrip Perspectives 2019 to 2020

In the second installment of Scrip’s preview of 2020 as outlined to us by more than 80 industry participants, we focus on investment and business strategy. Generally positive views fueled by the current wave of breakthrough science were tempered by the perceived need for technological innovation to be accompanied by enhancements in manufacturing cost and efficiency, and by potential attacks on the industry during the US presidential election campaign. 

Analysts at Jefferies Equity Research have a positive outlook for the pharma sector for 2020, noting in a 17 December...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip